Nl-Fr
All indicated times are in Greece Time Zone Eastern European Time (EET) (UTC+02:00)
Find out what that is in  YOUR TIMEZONE play_circle_filled_white

IOIS 2021 Congress – Educational Industry Symposia

SANTEN

FRIDAY 12:00 Educational Industry-sponsored symposium - Santen
Welcome and introduction BODAGHI B
From initial diagnosis to assessing disease progression in DED ROLANDO M
How to implement a stepwise approach to the management of DED in clinical practice MESSMER E
Changing the PERSPECTIVE on DED treatment: evidence from the real-world setting GEERLING G
Q & A - All faculty
End of Session

 

NOVARTIS

FRIDAY 17:00 Educational Industry-sponsored symposium - Novartis
TITLE: nAMD Management - Expert Insights at Each Step Along the Patient Journey
Moderator BODAGHI B
Welcome BODAGHI B
Introduction to nAMD - Unmet need in patients with nAMD and anti-vascular endothelial growth factor (anti-VEGF) efficacy and safety PAVESIO C
Benefit/risk profile of brolucizumab KHORAMNIA R
Key findings that support informed treatments decisions along the patient journey KHANANI A
Case Study 1: Efficacy of brolucizumab in a patient with unresolved fluid despite previous anti-VEGF treatment NGUYEN Q
Case Study 2: Adverse event management in a brolucizumab patient resulting in reversal of vision loss NGUYEN Q
Conclusion

 

Affibody

SATURDAY 12:00 Educational Industry-sponsored symposium - Affibody
Moderator > Panel Discussion NGUYEN Q
Topic: IL-17 inhibition in the management of non-infectious uveitis
Introduction to the Affibody@technology BEJKER David CEO, Affibody
The ABY-035 molecule FREJD Fredrik CSO, Affibody
Unmet medical need in managing non-infectious uveitis: target therapy MISEROCCHI E
How to LINNAEA study may address the unmet medical need NGUYEN Q
Panel Discussion NGUYEN Q, MISEROCCHI E, ADAN A, BBODAGHI B
End of Session

 

Alimera Sciences

SATURDAY 17:00 Educational Industry-sponsored symposium - Alimera Sciences
Moderator / Chair PAVESIO C
TOPIC: Preventing relapse in non-infectious uveitis affecting the posterior segment of the eye - evaluating the 0.2 μg/day fluocinolone acetonide intravitreal implant – lessons learned in the last 2 years
Welcome & Introductions PAVESIO C
The French Experience BODAGHI B
The German Experience KHORAMNIA R
The USA Experience NGUYEN Q
Q & A
End of Session